Thyroid cancers are the most common tumor associated with clonal hematopoiesis (CH), and CH is associated with worse outcomes in other solid tumor patients, although the specific consequences of CH on therapy response are unknown. Dr. Tiedje has developed a mouse model of concurrent CH and thyroid cancer to study the impact of CH on thyroid tumor biology and therapy response.
published research
Tiedje V, Greenberg J, Qin T, Im SY, Krishnamoorthy GP, Boucai L, Xu B, French JD, Sherman EJ, Ho AL, de Stanchina E, Socci ND, Jin J, Ghossein RA, Knauf JA, Koche RP, Fagin JA. Loss of tumor cell MHC Class II drives MAPK-inhibitor insensitivity of BRAF-mutant anaplastic thyroid cancers. J Clin Invest. 2025.